Avid Bioservices (NASDAQ: CDMO) reported Q4 EPS of $0.00, $0.01 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $39.8 million versus the consensus estimate of $38.91 million.

GUIDANCE:

Avid Bioservices sees FY2024 revenue of $145-165 million, versus the consensus of $181.27 million.

For earnings history and earnings-related data on Avid Bioservices (CDMO) click here.